IP Library Granted Patent US 12679846
Granted Patent B2
US 12679846 · App. 18/565,799 · Granted Jul 14, 2026

Xanthone compound having excellent anticancer effect

Inventors: Hee Jae Shin (Busan, KR); Byeoung Kyu Choi (Chungcheongnam-do, KR); Hwa Sun Lee (Busan, KR)
Assignee: KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY
C07D493/04A61P35/00C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679846
App. No.
18/565,799
Granted
Jul 14, 2026
Kind
B2
Abstract

The present invention relates to a novel xanthone compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof that exhibits cytotoxicity against cancer cell lines and inhibits cancer cell growth, thereby exhibiting excellent preventive or therapeutic effects on various cancer cells.

Claims (8)

1 . A xanthone compound represented by Formula A, Formula B or Formula C, an optical isomer thereof, or a pharmaceutically acceptable salt thereof:

wherein R and R′ are each independently substituted or unsubstituted C 1-10 alkyl or —COR 2 , and

R 2 is hydrogen, substituted or unsubstituted C 1-10 alkyl or C 6-30 aryl group).

2 . The xanthone compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1 , wherein the xanthone compound represented by Chemical Formula 1 is isolated from a strain Actinomadura geliboluensis 188DD-028 (strain accession number: KCTC 14764BP) or a culture medium thereof.

3 . A pharmaceutical composition for treating cancer comprising at least one selected from the group consisting of the xanthone compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1 .

4 . The pharmaceutical composition of claim 3 , wherein the cancer is at least one selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell cancer, ovarian cancer, ovarian epithelial cancer, ovarian germ cell cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, diffuse large B-cell lymphoma, ampullar of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, sinonasal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, tongue cancer, astrocytoma, small cell lung cancer, childhood brain cancer, childhood lymphoma, childhood leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, neuroblastoma, renal pelvis cancer, kidney cancer, heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, stomach cancer, gastric carcinoid, gastrointestinal cancer, Wilms cancer, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational trophoblastic disease, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, mesothelioma, rectal cancer, rectal carcinoid, vaginal cancer, spinal cord cancer, acoustic neuroma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsillar cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, and thymic cancer.

5 . A method for treating cancer-related diseases comprising administering at least one selected from the group consisting of the xanthone compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1 to a subject in need thereof.

6 . The method of claim 5 , wherein the cancer-related disease is at least one selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell cancer, ovarian cancer, ovarian epithelial cancer, ovarian germ cell cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, diffuse large B-cell lymphoma, ampullar of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, sinonasal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, tongue cancer, astrocytoma, small cell lung cancer, childhood brain cancer, childhood lymphoma, childhood leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, neuroblastoma, renal pelvis cancer, kidney cancer, heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, stomach cancer, gastric carcinoid, gastrointestinal cancer, Wilms cancer, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational trophoblastic disease, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, mesothelioma, rectal cancer, rectal carcinoid, vaginal cancer, spinal cord cancer, acoustic neuroma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsillar cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, and thymic cancer.